Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials
- 1 February 2017
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (1) , 48-58
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- GLP-1 based agents and acute pancreatitisBMJ, 2013
- Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsBMJ, 2011
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewBMJ, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registryThe American Journal of Cardiology, 1996
- Role of diabetes in congestive heart failure: The Framingham studyThe American Journal of Cardiology, 1974